within Pharmacolibrary.Drugs.ATC.L;

model L04AX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.00016999999999999999,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00074,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00535,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Thalidomide is an immunomodulatory drug originally developed as a sedative, later infamous for causing birth defects. It is now approved in several countries, including the United States, as part of treatment for multiple myeloma and for erythema nodosum leprosum (ENL) associated with leprosy. Thalidomide exhibits anti-inflammatory, anti-angiogenic, and immunomodulatory effects.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult males after a single oral dose.</p><h4>References</h4><ol><li><p>Smith, SL, et al., &amp; Chambers, JP (2016). Thalidomide pharmacokinetics in sheep. <i>New Zealand veterinary journal</i> 64(4) 238–242. DOI:<a href=\"https://doi.org/10.1080/00480169.2015.1130663\">10.1080/00480169.2015.1130663</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26727254/\">https://pubmed.ncbi.nlm.nih.gov/26727254</a></p></li><li><p>Teo, SK, et al., &amp; Laskin, OL (2004). Clinical pharmacokinetics of thalidomide. <i>Clinical pharmacokinetics</i> 43(5) 311–327. DOI:<a href=\"https://doi.org/10.2165/00003088-200443050-00004\">10.2165/00003088-200443050-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15080764/\">https://pubmed.ncbi.nlm.nih.gov/15080764</a></p></li><li><p>Kuwagata, M, et al., &amp; Yamazaki, H (2021). Pharmacokinetics of primary metabolites 5-hydroxythalidomide and 5&#x27;-hydroxythalidomide formed after oral administration of thalidomide in the rabbit, a thalidomide-sensitive species. <i>The Journal of toxicological sciences</i> 46(12) 553–560. DOI:<a href=\"https://doi.org/10.2131/jts.46.553\">10.2131/jts.46.553</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34853241/\">https://pubmed.ncbi.nlm.nih.gov/34853241</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AX02;
